Cargando…
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
INTRODUCTION: In a retrospective analysis of two randomized phase III trials in mCRC patients treated first line with oxaliplatin, fluoropyrimidine with and without Bevacizumab (the AIO KRK 0207 and R091 trials) we evaluated the association of high microsatellite instability (MSI-H), immunoscore (IS...
Autores principales: | Noepel-Duennebacke, Stefanie, Juette, Hendrik, Schulmann, Karsten, Graeven, Ulrich, Porschen, Rainer, Stoehlmacher, Jan, Hegewisch-Becker, Susanna, Raulf, Arne, Arnold, Dirk, Reinacher-Schick, Anke, Tannapfel, Aandrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397637/ https://www.ncbi.nlm.nih.gov/pubmed/33675399 http://dx.doi.org/10.1007/s00432-021-03559-w |
Ejemplares similares
-
Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018) -
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
por: Reinacher-Schick, Anke, et al.
Publicado: (2012) -
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020) -
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016) -
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
por: Stein, Alexander, et al.
Publicado: (2013)